Next Article in Journal
Ultrasound-Assisted Extraction of Bioactive Compounds from Strawberry Pomace: Optimization and Bioactivity Assessment
Previous Article in Journal
Correction: Zengin et al. Comprehensive Biological and Chemical Evaluation of Two Seseli Species (S. gummiferum and S. transcaucasicum). Antioxidants 2021, 10, 1510
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 15
Issue 1
10.3390/antiox15010048
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status

by
Fátima Martel
1,2
1
Unit of Biochemistry, Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2
Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, 4200-135 Porto, Portugal
Antioxidants 2026, 15(1), 48; https://doi.org/10.3390/antiox15010048 (registering DOI)
Submission received: 27 November 2025 / Revised: 19 December 2025 / Accepted: 23 December 2025 / Published: 30 December 2025
(This article belongs to the Special Issue Redox Regulation of Membrane Transporters: Mechanisms and Implications)
Browse Figures
Versions Notes

Abstract

Beneficial effects of the microbiota-derived metabolite butyrate at the colonic level are well established, particularly through its relevance in colorectal cancer (CRC) and inflammatory bowel disease (IBD), two major intestinal pathologies. Therefore, the mechanisms involved in butyrate transport across colonic epithelial cell membranes (uptake transporters: monocarboxylate transporter 1 (MCT1) and sodium-coupled monocarboxylate transporter 1 (SMCT1); efflux transporters: breast cancer resistance protein (BCRP) and MCT1/monocarboxylate transporter 4 (MCT4)), which are determinant for its intracellular levels, are of primary importance for its beneficial effects at the colonic level. The available data suggest that all these butyrate transporters can be modulated by redox and inflammatory status, but the evidence is scarce and rather inconsistent. Nevertheless, a role of nuclear factor erythroid 2-related factor 2 (Nrf2) and of the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in mediating the effect of oxidative stress and inflammation, respectively, on MCT1 and SMCT1 is suggested. So, more investigation on this subject is needed, given the fact that increased oxidative stress levels and inflammatory status are present in a series of intestinal conditions and pathologies, including CRC and IBD, which could help to establish these transporters as potential cellular targets in these diseases.

Graphical Abstract

1. Introduction—The Role of Butyrate in the Human Intestine

Butyrate, along with the two other short-chain fatty acids (acetate and propionate), is a product of intestinal fermentation of dietary fiber by the microbiota and plays a crucial role in maintaining colonic epithelial homeostasis. Butyrate exerts multiple regulatory and beneficial effects within the colon, including the fact that this short-chain fatty acid: (1) is the preferred energy substrate for colonocytes; (2) stimulates growth and proliferation of normal intestinal epithelial cells; (3) inhibits inflammation; (4) inhibits oxidative stress; (5) improves the defense barrier function; (6) stimulates mucus secretion; (7) stimulates fluid and electrolyte absorption; and (8) inhibits colon carcinogenesis [1,2].
The beneficial actions of butyrate at the intestinal level result from its effect on epithelial and immune cells resulting from two distinct, but complementary, pathways: binding to G-protein-coupled receptors (GPR41, GPR43, and GPR109A) and inhibition of histone deacetylases (HDACs), thereby influencing gene transcription [1,2]. Therefore, the mechanisms involved in BT transport across biological membranes at the intestinal level (including both uptake and efflux mechanisms) and their regulation are very relevant in the context of the beneficial effects of this compound at the colonic level.

2. Membrane Transport of Butyrate in the Intestinal Epithelium

Undissociated butyrate can passively diffuse across the lipid membrane of colonocytes. However, since more than 90% of butyrate (pKa of ≅ 4.8) is ionized at luminal pH (≅6.0), this mechanism plays a very limited physiological role in its transport. Instead, transport of this compound across intestinal cell membranes is mainly mediated by transport systems [2,3,4,5,6]. At the intestinal level, two major monocarboxylate transporters, belonging to distinct transporter families, have been identified for butyrate absorption across the luminal membranes of colonocytes. These transporters are the proton-coupled electroneutral monocarboxylate transporter 1 (MCT1, SLC16A1) (H+: butyrate stoichiometry; 1:1) and the sodium-coupled electrogenic monocarboxylate transporter 1 (SMCT1, SLC5A8) (Na+: butyrate stoichiometry; 2:1) [2,3,4,5,6].
Additionally, MCT1 and MCT4 (SLC16A3; proton-coupled electroneutral monocarboxylate transporter 4) (H+: butyrate stoichiometry; 1:1), another transporter belonging to the SLC16 family, were identified in the basolateral membrane of colonic epithelium and may be involved in butyrate efflux from the colonocytes into the serosal side [6].
Moreover, butyrate is also a substrate of ABCG2 (also known as BCRP or breast cancer resistance protein), an ATP-dependent efflux pump expressed in the lumen-facing apical membrane of colonic epithelial cells, able to transport butyrate from the colonocytes into the intestinal lumen [7].
To summarize, butyrate is absorbed from the colon lumen into colonocytes by both MCT1- and SMCT1-mediated transport and can be apically and basolaterally removed from these cells, by BCRP- and MCT1/4-mediated mechanisms, respectively.

3. Regulation of Butyrate Transport by Oxidative Stress/Redox Levels

Increased reactive oxygen species (ROS) levels, also known as oxidative stress, are a result of either increased ROS generation and/or a loss of antioxidant defense mechanisms. A major consequence of oxidative stress is damage of tissue via direct oxidation of nucleic acid bases, lipids, and proteins, but also via profound alterations in signal transduction pathways, which can severely compromise cellular functions. Not surprisingly, it is associated with numerous pathologies, from atherosclerosis to neurodegenerative diseases, inflammation, and cancer [8,9,10,11].
The gastrointestinal tract is a major target for oxidative stress damage due to constant exposure to ROS generated not only by endogenous (cellular) sources but also by a large variety of xenobiotics (air pollutants, tobacco smoke, ionizing and non-ionizing radiations, heavy metals, foods, and drugs), endogenous toxic substances (e.g., bile acids), as well as by microbial and microbiota metabolism [12,13]. An imbalance in the cellular redox system leading to increased levels of ROS is associated with many gastrointestinal tract conditions or diseases, including ischemia/reperfusion, inflammatory bowel disease, surgical stress, radiation enteritis, iron supplementation, Zn deficiency, methotrexate therapy, and colorectal cancer (CRC) [12,14] (Figure 1).
Oxidative stress, and ROS in particular, can modulate transporter function by a number of mechanisms, including: (a) regulation of the expression of transporters at transcriptional, posttranscriptional, and epigenetic levels; (b) regulation of the biosynthesis of cofactors required for the transporter’s function; (c) posttranslational modifications of transporter structure/conformational changes in the transporter (e.g., formation of intra- or interprotein crosslinked derivatives, peptide cleavage, nitrosylation, nitration, and oxidation of key amino acid residues with production of hydroxyl or carbonyl derivatives); and (d) amplification of the copy number of genes encoding these transporters [15,16].
Although oxidative stress is a factor affecting the function and expression of many intestinal transporters [15,17], not much is known concerning the effect of an oxidative environment on intestinal butyrate transport (Table 1).
Our group investigated the effect of tert-butylhydroperoxide (tBOOH)-induced oxidative stress on butyrate uptake by rat intestinal epithelial cells (IEC-6 cells). We verified that tBOOH strongly reduced total and Na+-dependent butyrate uptake, but because it did not affect Na+-independent uptake, we concluded that it strongly reduced SMCT1-mediated, but not MCT1-mediated, butyrate uptake by these cells. The lack of effect of oxidative stress on MCT1 was substantiated by the fact that tBOOH did not interfere with butyrate uptake by Caco-2 cells, a human colorectal adenocarcinoma cell line in which butyrate uptake is mainly MCT1-mediated. Moreover, tBOOH increased uptake and efflux of butyrate by passive diffusion. We could also conclude, by using specific NADPH and xanthine oxidases inhibitors, that the inhibitory effect of oxidative stress upon SMCT1-mediated butyrate transport was dependent on the generation of ROS by these two enzymes. Moreover, we also verified that the inhibitory effect of oxidative stress upon SMCT1-mediated butyrate transport was not related to changes in either SMCT1 transcription rates or its membrane insertion. Rather, by using specific kinase inhibitors, we concluded that this inhibitory effect was dependent on posttranslational regulation by ERK1/2 and tyrosine kinase intracellular pathways. In contrast, it was not affected by specific inhibitors of protein kinase A, protein kinase C, Ca2+/calmodulin-dependent protein kinase II, c-Jun N-terminal kinase (JNK), and p38 MAPK. Importantly, the negative effect of oxidative stress upon butyrate uptake was partially prevented by quercetin and resveratrol, two dietary polyphenols with antioxidant properties [18].
In another work, we verified that the bile salt chenodeoxycholic acid was able to reduce both MCT1- and SMCT1-mediated butyrate uptake by IEC-6 cells. Interestingly, although the ROS scavenger N-acetylcysteine did not alter butyrate uptake, it was able to partially reduce the inhibitory effect of chenodeoxycholic acid, suggesting that the inhibition of butyrate transport by this bile salt is at least partly related to its pro-oxidant effect [19].
However, a contrasting effect was observed with another oxidative stress inducer, tert-butylhydroquinone (tBHQ). In both normal (non-cancerous) and cancerous intestinal epithelial cell lines (NCM460 and HCT15 cells, respectively), this agent led to an increase in MCT1 mRNA and protein levels (together with a decrease in MCT4 levels). Interestingly, the effect of tBHQ on MCT1 was associated with increased expression of Nrf2, a transcription factor that has a key role in the cellular response to oxidative stress, by inducing the expression of numerous antioxidant and detoxifying enzymes as well as genes involved in cell growth and survival. Treatment of NCM460 cells with small interfering RNA against Nrf2 decreased MCT1 expression, confirming the role of Nrf2 in MCT1 regulation in the colon [20] (Table 1).
The stimulating effect of Nrf2 activation on MCT1 appears not to be restricted to the intestine. Indeed, a similar Nrf2-dependent MCT1 activation was also described in C57BL/6 J mice, where administration of the Nrf2 activator sulforaphane led to an increase in MCT1 mRNA and protein levels in skeletal muscle. In contrast, the expression of MCT4 mRNA decreased after pretreatment with this compound, although it did not affect MCT4 protein expression [21]. Similarly, oxidative stress caused by glutamine depletion led to an Nrf2-dependent induction of MCT1 expression in pancreatic ductal adenocarcinoma T3M4 and A818-6 cell lines [22].
A contrasting effect of different oxidative stress generators on butyrate transporters was also verified in an amyotrophic lateral sclerosis (ALS) cell line model (a mutant motor neuron-like NSC-34 cell line). The authors verified that exposure of these cells to H2O2 or glutamate, two conditions that increase oxidative stress levels, led to opposite effects (increase and decrease, respectively) on SMCT1 mRNA levels and activity [23].
Finally, in the SiHa human cervix squamous carcinoma cell line, the MCT1 gene and protein expression were increased by the ROS generator H2O2, and this overexpression was blocked by both the antioxidant N-acetyl-L-cysteine and the mitochondria-selective superoxide scavenger MitoTEMPO [24].
Very little is known concerning the effect of redox state on BCRP-mediated butyrate transport at the intestinal level. The only study on this subject concluded that tBOOH does not interfere with BCRP-mediated butyrate efflux from IEC-6 cells [18]. Nevertheless, the consequences of oxidative stress on intestinal BCRP levels have been investigated in a few studies, although the results are not straightforward. While some oxidative stress inducers (doxorubicin alone or in combination with CoCl) were reported to increase BCRP protein levels in wild-type and doxorubicin-resistant HT-29 cells [25], a reduction in BCRP levels was found with other oxidative stress inducers (e.g., inosine, hypoxanthine, and hypericin + 6 h photodynamic therapy) in rat ileum and human colon adenocarcinoma Caco-2 and HT-29 cell lines [26,27]. The same discrepant effect of distinct oxidative stress inducers on BCRP in other organs has also been found [28,29,30,31].
Overall, we conclude that different oxidative stress inducers appear to induce distinct changes in MCT1-, SMCT1-, and BCRP-mediated butyrate transport both at the colonic and extra-colonic level. The discrepancy may be related to differences in the mechanisms involved in generating increased oxidative stress levels (such as differences in the ROS species generated or in the ROS-generating mechanism) or differences in the modulation of antioxidant defenses. Moreover, it can also result from the fact that the effect of oxidative stress inducers was frequently evaluated by using compounds with many other biological actions.
Table 1. Effect of increased oxidative stress levels and inflammation on butyrate transporters at the intestinal level. Symbols: ↑ increase, ↓ decrease, = no effect, - not determined.
Table 1. Effect of increased oxidative stress levels and inflammation on butyrate transporters at the intestinal level. Symbols: ↑ increase, ↓ decrease, = no effect, - not determined.
TransporterOxidative Stress Inducer(s)Experimental ModelObserved EffectMechanismRef.
 SMCT1 
  • tBOOH (3 mM; 1 h)
IEC-6 cells↓
  • Decrease in SMCT1-mediated butyrate uptake; no effect on MCT1-mediated uptake
  • No effect on SMCT1 mRNA level
  • No effect on SMCT1 membrane insertion rate
  • Posttranslational (dependent on regulation by ERK1/2 and tyrosine kinase intracellular pathways)
[18]
MCT1Caco-2 cells=
  • No effect on MCT1-mediated uptake
MCT1
  • Chenodeoxycholic acid (100 µM; 48 h)
IEC-6 cells↓
  • Decrease in MCT1- and SMCT1-mediated butyrate uptake
  • No effect on MCT1 mRNA levels
[19]
SMCT1↓
  • Increase in SMCT1 mRNA levels
MCT1
  • tBHQ (50 µM; 24–72 h)
NCM460 cells,
HCT15 cells		↑
  • Increase in MCT1 mRNA and protein levels
  • This effect is Nrf2 activation-dependent
[20]
MCT4↓
  • Decrease in MCT4 mRNA and protein levels
BCRP
  • tBOOH (3 mM; 1 h)
IEC-6 cells=
  • -
[18]
BCRP
  • Doxorubicin (5 µM; 24 h)
  • CoCl (100 µM; 24 h)) (chemically induced hypoxia)
  • Doxorubicin (5 µM) + CoCl (100 µM) (24 h)
HT-29wt cells,
HT-29DxR (doxorubicin-resistant) cells		↑
  • Increase in BCRP protein levels
  • ROS-dependent
[25]
BCRP
  • Inosine (2% in diet; 24 h)
Rat ileum↓
  • No change in BCRP mRNA and protein levels
  • Decrease in BCRP homodimer levels
  • Dependent on xanthine-oxidase-derived ROS
[26]
  • Hypoxanthine (1–5 mM; 3 h)
Caco-2 cells↓
  • No change in BCRP mRNA and protein levels
  • Decrease in BCRP homodimer levels
  • Dependent on xanthine-oxidase-derived ROS
BCRP
  • Hypericin (50 nM) (16 h) + 6h Photodynamic therapy
  • Hypericin (50 nM) + Hyperforin (1–5 µM) (16 h) + 6h Photodynamic therapy
  • Hypericin (50 nM) + Aristoforin (1–5 µM) (16 h) + 6h Photodynamic therapy
HT-29 cells↓
  • Decrease in BCRP mRNA and protein levels
[27]
TransporterExperimental Model/
Inflammatory Mediator		Observed EffectMechanismRef.
MCT1
  • Inflamed colonic mucosa of patients with active UC (vs. control subjects)
↓
  • Decrease in butyrate uptake and oxidation
  • Decrease in MCT1 mRNA levels
[32]
MCT1
  • Inflamed colonic mucosa of patients with active UC (vs. non-inflamed mucosa and control subjects)
↓
  • Decrease in MCT1 and BCRP mRNA levels
  • The decrease in MCT1 and BCRP levels is > than in non-inflamed colonic mucosa
[33]
BCRP↓/=
  • Decrease in protein levels of MCT1
  • No change in protein levels of BCRP
MCT1
  • Inflamed colonic mucosa of patients with active UC and CD (vs. control subjects)
↓
  • Decrease in MCT1 and BCRP mRNA and protein levels
[34]
 BCRP 
  • Ex vivo differentiated epithelial organoids from healthy individuals/TNF-α (50 ng/mL; 24 h)
↓
  • TNF-α decreased butyrate uptake and beta-oxidation
  • TNF-α decreased MCT1 and BCRP mRNA levels
 MCT1 
  • Inflamed colonic mucosa of patients with active UC and CD (vs. non-inflamed mucosa and control subjects)
↓
  • Decrease in MCT1 mRNA and protein levels
  • The decrease in MCT1 levels is > than in non-inflamed colonic mucosa
[35]
  • Rats with DSS-induced colitis
↓
  • Decrease in MCT1 mRNA and protein levels
  • HT-29 cells/TNF-α (30–100 ng/mL), IFN-γ (300–1000 U/mL) (24 h)
↓
  • TNF-α and IFN-γ decrease butyrate uptake and oxidation
  • TNF-α and IFN-γ decrease MCT1 mRNA and protein abundance
  • TNF-α and IFN-γ decrease MCT1 gene transcription and had no effect on MCT1 mRNA stability
SMCT1
  • Inflamed colonic mucosa of patients with active UC and CD (vs. non-inflamed mucosa)
=
  • No change in SMCT1 mRNA levels
[36]
 SMCT1 
  • IEC-6 cells and Caco-2 cells/TNF-α (5–10 ng/mL) (24 h)
↓
  • TNF-α decreases SMCT1-mediated butyrate transport and SMCT1 mRNA levels in IEC-6 cells
  • TNF-α decreased SMCT1 promoter activity in Caco-2 cells
[37]
  • Mice with DSS-induced colitis
↓
  • Decrease in SMCT1 mRNA and protein levels
MCT1
  • Mice with DSS-induced colitis
↓
  • Decrease in MCT1 mRNA levels
[38]
MCT4↑
  • Increase in MCT4 mRNA levels
MCT1
  • Mice with T cell transfer-induced colitis
↓
  • Decrease in MCT1 mRNA levels
[39]
SMCT1↓
  • Decrease in SMCT1 mRNA levels
MCT1
  • Mice with DSS-induced colitis
↓
  • Decrease in MCT1 mRNA levels
[40]
MCT1
  • Caco-2 cells/TNF-α, IFN-γ (100 ng/mL) (24 h)
↓
  • Decrease in MCT1-mediated butyrate transport
  • No change in MCT1 mRNA levels
[41]
MCT1
  • Caco-2 cells/TNF-α, INF-γ (200 ng/mL) (24 h)
↓/↑
  • TNF-α and INF-γ decrease MCT1-mediated transport of butyrate (10 μM)
  • INF-γ increases MCT1-mediated transport of butyrate (10 mM)
[42]
MCT1
  • Ex vivo porcine colonic tissue/TNF-α (50 ng/mL; 1 h)
  • Caco-2 cells/TNF-α (25–100 ng/mL; 1 h)
↓
  • Decrease in MCT1 mRNA levels
[43]
MCT1
  • Primary rat colonic epithelial cells/TNF-α (500 pg/mL) (24 h)
↓
  • Decrease in MCT1 mRNA levels
[44]
MCT4↓
  • Decrease in MCT4 mRNA levels
MCT1
  • HT-29 cells/TNF-α (50 ng/mL), IFN-γ (100 ng/mL) (24 h)
↓
  • Decrease in butyrate uptake and oxidation
  • No effect on MCT1 mRNA levels
[45]
MCT1
  • NCM460 cells/indirect coculture with M1 human macrophages (24 h)
↑
  • Increase in MCT1 mRNA levels; this effect is Nrf2 activation-dependent
[20]
MCT4↓
  • Decrease in MCT4 mRNA levels
MCT1
  • Ex vivo calves’ ruminal epithelial tissue/LPS
=
  • No change in MCT1 mRNA levels
[46]
SMCT1
  • No change in SMCT1 mRNA levels
BCRP
  • Inflamed colonic mucosa of patients with active CD and UC (vs. non-inflamed mucosa and control subjects)
↓
  • Decrease in BCRP protein levels
  • The decrease in BCRP levels is > than in non-inflamed colonic mucosa
  • No change in BCRP mRNA levels
  • The effect is mediated by inflammation-dependent activation of the unfolded protein response
[47]
BCRP
  • Inflamed colonic mucosa of patients with active UC (vs. non-inflamed mucosa and control subjects)
↓
  • Decrease in BCRP mRNA levels
  • The decrease in BCRP levels is > than in non-inflamed colonic mucosa
[48]
BCRP
  • Inflamed colonic mucosa of patients with active UC (vs. non-inflamed mucosa)
↓
  • Decrease in BCRP mRNA levels
[49]
MCT4
  • Colonic mucosa of patients with active CD and UC (vs. non-inflamed mucosa and control subjects)
↑
  • Increase in MCT4 protein levels
  • The increase in MRP4 levels is > than in non-inflamed colonic mucosa
[50]
MCT4
  • Colonic mucosa of patients with active UC
    (vs. control subjects)
  • Mice with DSS-induced colitis
↑
  • Increase in MCT4 protein levels
[51]
Abbreviations: BCRP: breast cancer resistance protein; CD: Crohn’s disease; DSS: dextran sulfate sodium; ERK1/2: extracellular signal-regulated kinases 1 and 2; IFN-γ: interferon-γ; LPS: lipopolyssacharide; MCT1: monocarboxylate transporter 1; MCT4: monocarboxylate transporter 4; Nrf2: nuclear factor erythroid 2-related factor 2; ROS: reactive oxygen species; SMCT1: sodium-coupled monocarboxylate transporter 1; tBOOH: tert-butylhydroperoxide; tBHQ: tert-butylhydroquinone; UC: ulcerative colitis; TNF-α: tumor necrosis factor-α.

4. Regulation of Butyrate Transport by Inflammation

Intestinal inflammation has a complex and multifactorial etiology, resulting from a breakdown in the delicate homeostatic balance between the host’s immune system, the gut microbiota, and various environmental factors. Sources of acute or chronic inflammation at the intestinal level include host genetic predispositions (e.g., mutations in genes that affect immune function and the mucosal barrier), disruptions in gut microbiota composition (dysbiosis), infectious agents (including bacterial, viral, and parasitic pathogens), ischemia, radiation enteritis and environmental factors such as Western diets high in processed fats and sugars, poorly tolerated fermentable carbohydrates, non-steroidal anti-inflammatory drugs (NSAIDs), certain food additives, antibiotic use, and smoking [52,53] (Figure 2).
Inflammatory bowel diseases (IBDs) are a group of life-threatening chronic diseases of the gastrointestinal tract characterized by episodes of intestinal inflammation, with Crohn’s disease (CD) and ulcerative colitis (UC) being the most significant. The incidence and prevalence of IBD, an immune-mediated condition, markedly increased over the second half of the 20th century, and since the beginning of the 21st century, IBD has been considered one of the most prevalent gastrointestinal diseases with accelerating incidence in newly industrialized countries [54,55]. The etiology and pathogenesis of IBD is multifactorial, with genetic susceptibility, environmental factors such as tobacco or NSAID use, gut microbiota dysbiosis, barrier dysfunction, immune dysregulation (with increased levels of proinflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α)), and increased oxidative stress levels being involved [56,57].
A summary of the effect of inflammation/inflammatory mediators on intestinal butyrate transporters is shown in Table 1.
The inflamed intestinal mucosa of patients with IBD is characterized by reduced butyrate metabolism (oxidation), associated with a decrease in butyrate cellular uptake through MCT1 downregulation [32,33,34,35]. Of note, MCT1 is downregulated in the inflamed mucosa to a greater degree than in non-inflamed mucosa of UC and CD patients [33,35]. Interestingly, infliximab (an anti-TNF-α monoclonal antibody) markedly increased MCT1 mRNA levels in the inflamed colon of infliximab-responsive UC patients [32]. In relation to SMCT1, information is scarce, but no alteration in SMCT1 mRNA levels was reported in the inflamed colon of UC patients [36].
Additionally, a decrease in MCT1 and SMCT1 gene expression is observed in colitis-induced rodent models [35,37,38,39,40].
The inhibitory effect of an inflammatory environment on butyrate uptake at the intestinal level appears to result from the action of the proinflammatory cytokines TNF-α and IFN-γ, which have been shown to reduce butyrate uptake and oxidation in intestinal epithelial cell lines in vitro and colonic epithelial organoid cultures and colonic tissue ex vitro [34,35,37,41,42]. However, these effects may depend on the luminal concentration of butyrate. Indeed, our group verified that, although uptake of BT (10 µM) by Caco-2 cells was inhibited by both TNF-α and INF-γ, INF-γ increased uptake of a high concentration of butyrate (10 mM) in these cells [42]. Besides TNF-α and IFN-γ, IL-1β also appears to reduce butyrate oxidation in an intestinal epithelial cell line [58].
Multiple studies strongly suggest that the inhibitory effect of these two proinflammatory cytokines on butyrate uptake results from downregulation of MCT1 and SMCT1 gene expression [34,35,37,43,44]. Interestingly, while TNF-α treatment decreased both SMCT1 mRNA expression levels and butyrate uptake by intestinal epithelial cells (IEC-6 cells), pretreatment with Lactobacilli plantarum significantly attenuated the inhibitory effects of TNF-α on SMCT1 [37]. Reduced colonic expression of SMCT1 and butyrate transport were also found in spontaneously hypertensive rats, a model presenting with high colonic TNF-α levels [59,60]. However, two reports did not find an effect of TNF-α and IFN-γ on MCT1 mRNA expression levels [41,45].
So, while most available data show that the decrease in butyrate uptake by inflammatory cytokines is probably related to a reduction in the transcription rates of MCT1 and SMCT1, more investigation is needed in order to confirm this. Specifically, investigating whether these cytokines influence the transporters posttranscriptionally—through modulation of membrane insertion or intracellular signaling-dependent regulation—would be of particular interest.
However, an opposite effect of inflammatory mediators on MCT1, namely an induction, was described by Diehl et al. [20]. In this work, it was verified that indirect coculture of a normal human intestinal epithelial cell line (NCM460) with M1 (classically activated), but not M2, human macrophages induced Nrf2 activation-dependent MCT1 expression. In contrast, MCT4 expression was reduced. It was also verified that Nrf2 knockdown or ROS scavenging blocked these coculture effects in NCM460 cells [20]. However, it must be pointed out that the effect of pure cytokines was not evaluated; instead, an indirect coculture experimental model was used, in which NCM460 cells were exposed to M1 macrophage secretions, which are known to include high levels of proinflammatory cytokines and chemokines such as TNF-α, interleukin-6 (IL-6), interleukin-1β (IL-1β), interleukin-12 (IL-12), and C-X-C motif chemokine ligand 10 (CXCL10), among other substances [61]. It is thus possible that other compounds secreted by M1 macrophages, besides TNF-α, are also able to affect MCT1 gene expression, thus explaining the overall stimulatory effect observed.
In contrast, no significant effect on butyrate transport activity and MCT1 and SMCT1 gene expression occurred after ex vivo exposure of calves’ ruminal epithelial tissue to lipopolysaccharide (LPS), a structural component of the outer membrane of Gram-negative bacteria that acts as a potent trigger of the inflammatory response [46]. A contrasting effect of TNF-α and LPS on butyrate transporters was also verified in an ALS cell line model (mutant motor neuron-like NSC-34 cell line), where TNF-α increased SMCT1 mRNA levels and transport activity, whereas LPS caused an opposite effect on both SMCT1 mRNA levels and activity [23].
As mentioned before, BCRP and MCT4 also modulate butyrate intracellular concentrations, because BT is a substrate of these two transporters at the colonic epithelial level. However, information on the influence of inflammation on these two transporters is scarce.
In relation to BCRP, the mRNA and protein levels of this ABC transporter were found to be strongly reduced in the inflamed intestine and colon of IBD patients, not only in relation to control subjects but also in relation to biopsies from non-inflamed mucosa of IBD patients [33,34,47,48,49]. Moreover, the inflammatory mediator nitric oxide was described to activate the unfolded protein response and concomitantly reduce the plasma membrane localization as well as the transport function of ABCG2 [47].
As for MCT4, analysis of human data shows that the expression of MCT4 is upregulated in IBD [50,51], being the same trend observed in rodent models of colitis [38,51]. However, an opposite effect was found with primary rat colonic epithelial cells, where TNF-α was able to reduce MCT4 mRNA levels [44].
Although regulation of butyrate transporter expression has been mostly studied in vitro in intestinal epithelial cells, LPS and TNF-α were reported to induce MCT1 mRNA and protein expression in mouse peritoneal and J774.1 macrophages [62]. On the basis of this report, inflammation appears to have opposite effects on MCT1-mediated transport of butyrate in colonic intestinal epithelial cells and peritoneal inflammatory macrophages.
Finally, the effect of NSAIDs upon MCT1 and SMCT1 was previously investigated in a few studies. MCT1 activity is inhibited by several NSAIDs (including salicylic acid, acetylsalicylic acid, diflunisal, diclofenac, ketoprofen, indomethacin, and naproxen) [63,64,65,66,67,68,69]. In contrast, our group verified that butyrate uptake by Caco-2 cells (mainly MCT-1 mediated) was stimulated by acetylsalicylic acid [43]. As for SMCT1, this transporter is also inhibited by some NSAIDs (including ibuprofen, ketoprofen, fenoprofen, and naproxen) [70,71,72,73] while stimulated by others (diclofenac, meclofenamate, and sulindac) [74]. These distinct effects of several NSAIDs on both MCT1 and SMCT1 point to the possibility that their distinct effects are related to other effects than their anti-inflammatory effect.

5. Relevance of Redox Modulation of Butyrate Transport on Butyrate-Mediated Effects

The beneficial effects of butyrate at the intestinal level include anti-inflammatory and anticarcinogenic actions. Accordingly, a protective effect of this SCFA against CRC and IBD, two of the most significant intestinal diseases affecting humans, due to their high prevalence and substantial impact on morbidity and mortality, is well established [1,2,75].
CRC is a malignant disease that develops from the uncontrolled growth of abnormal cells in the lining of the colon or rectum. In 2023, CRC constituted the third most common cancer worldwide, accounting for approximately 10% of all cancer cases, being the second leading cause of cancer-related deaths worldwide [76]. As for IBD, as already stated, it is a chronic inflammatory disease of the gastrointestinal tract, requiring lifelong medication and often causing significant morbidity [54,55]. These two intestinal diseases are linked, as chronic inflammation is known to promote carcinogenesis, and patients with IBD are at increased risk for developing CRC [77,78]. This is clearly demonstrated by the fact that although IBD-related CRC is responsible for only approximately 2% of the annual mortality from CRC overall, CRC is responsible for 10–15% of annual deaths in IBD patients [79].
Importantly, butyrate transporters are altered in these two diseases. In IBD, a downregulation of MCT1 and SMCT1 is observed, highlighting the essential contribution of MCT1- and SMCT1-mediated butyrate transport into colonocytes for its anti-inflammatory activity (see Section 4). In relation to CRC, a downregulation of MCT1 (in the early stages of carcinogenesis) and SMCT1 is observed [2,5,6], supporting a crucial role of MCT1- and SMCT1-mediated butyrate uptake by colonocytes for its anticarcinogenic effects. Accordingly, colonic MCT1 and SMCT1 have been proposed to function as tumor suppressors [2,80,81]. However, although downregulation of MCT1 is observed in initial stages of CRC development, a later upregulation of MCT1 in advanced metastatic CRC tumors has been described [82,83,84], possibly providing a route for excess lactate produced by CRC cells to leave the cell [84]. As for BCRP, its mRNA and protein expression are significantly downregulated in human colorectal adenomas and CRC and in mouse models of CRC, suggesting that malignant transformation of the colonic epithelium in vivo is accompanied by a significant downregulation of BCRP. However, similarly to MCT1, some studies described BCRP overexpression in invasive CRC (i.e., advanced stage of carcinogenesis) [85,86,87].
As mentioned above, the molecular targets for butyrate at the intestinal level are located on the cell surface as well as inside cells. More specifically, both in colonic epithelial cells and mucosal immune cells, three cell-surface G-protein-coupled receptors, GPR41, GPR43, and GPR109A, are targets for butyrate [1,2]. Because these receptors are present in the lumen-facing apical membrane of colonic epithelium, luminal butyrate is able to stimulate these receptors without the need to enter the cells. In addition to these extracellular actions, butyrate also has intracellular actions (HDAC inhibition), which obviously requires its uptake into colonic epithelial cells. Furthermore, butyrate needs to traverse the colonic epithelial cells to the serosal side to act on the immune cells present in the lamina propria. Therefore, butyrate transporters expressed in colonic mucosa are major determinants of the anticarcinogenic and anti-inflammatory beneficial effects of this SCFA [1,2,6]. Some works clearly demonstrate this relationship. For instance, Thangaraju et al. verified that re-expression of SMCT1 in SW480 CRC cells, in which SMCT1 was completely silenced, restored butyrate transport and induced apoptosis, but only in the presence of butyrate [88]. Moreover, our group verified that the bile salt chenodeoxycholic acid, which was able to inhibit both MCT1- and SMCT1-mediated butyrate uptake by IEC-6 cells, reduced the cytotoxic effect and the prodifferentiation effect of this compound [19]. Finally, we also verified that inhibition of BCRP significantly potentiated the inhibitory effect of butyrate upon intestinal epithelial IEC-6 cell proliferation [7].
In this context, a few works investigated the consequences of changes in butyrate transporter function induced by redox modulators or inflammatory mediators on its anticarcinogenic and anti-inflammatory actions.
In relation to the effect of redox modulators on the colonic effects of butyrate, given the important protective roles played by butyrate at this level against CRC and IBD, it is plausible to conclude that a decrease in cellular butyrate uptake caused by increased oxidative stress levels, as observed by our group [18], will obviously contribute to the procarcinogenic and proinflammatory effect of oxidative stress at this level. However, this has not been yet investigated. Indeed, the effect of redox status has been investigated to date only in a few works that tested the effect of polyphenols on butyrate actions at the colonic level. Dietary polyphenols are a large family of compounds with antioxidant, anti-inflammatory, and anticarcinogenic characteristics [89]. An interesting work described that long-term (48–72 h) treatment of HT-29 CRC cells with the polyphenols epicatechin (EC) (100 µM) or epigallocatechin-3-gallate (EGCG) (20 µM) reduced butyrate-induced cellular differentiation, associated with a reduction in the cellular uptake of butyrate. Importantly, it was also verified that this effect was not related to changes in MCT1 expression but rather to its membrane localization [90]. The effect of these two polyphenols in another colorectal cancer cell line (Caco-2 cells) was, however, rather distinct. EC did not show a consistent effect upon butyrate uptake and EGCG decreased butyrate uptake in the short term (23 min; 10 µM) but increased it in the long term (48 h; 1–10 µM). Surprisingly, the increase in butyrate uptake induced by EGCG was associated with a decrease in butyrate oxidation and MCT1 mRNA levels. Moreover, EGCG did not interfere with the effect of butyrate on Caco-2 cell viability, cell proliferation, differentiation, and apoptosis [91]. The differences between the results of these two works might be related to the fact that distinct CRC cell lines were used, because similar exposure times and concentrations of the polyphenols were used. Moreover, it is also important to mention that no evidence was presented showing that the effect of these polyphenols on butyrate transport and butyrate-induced cellular effects is related to redox alterations only. Although the anticarcinogenic effect of polyphenols is strongly related to their redox modulating effect, these compounds possess many other biological activities (e.g., they are anti-inflammatory, epigenetic modulators and they interfere with cell signaling pathways and with mitochondrial function) that may contribute to their anticancer effect [92,93]. Moreover, numerous studies show beneficial effects of flavonoids as potent antioxidants under normal conditions but as having potent pro-oxidant properties in cancer cells [92]. So, direct evidence linking redox modulation by these compounds to changes in butyrate transporter function and subsequent biological outcomes is currently lacking and constitutes a knowledge gap.
In relation to inflammation, our group verified that, in Caco-2 cells, the antiproliferative effect of BT, but not its cytotoxic effect, is MCT1-dependent. In these same cells, we observed that the antiproliferative effects of butyrate and of proinflammatory cytokines (which inhibited MCT1-mediated butyrate uptake) were not additive, evidencing a common cellular molecular target. In contrast, the cytotoxic effects of BT and of the proinflammatory cytokines were additive [41]. This clearly links an inflammatory environment, and more specifically the proinflammatory cytokines TNF-α and IFN-γ, to a decrease in MCT1-mediated colonic uptake of butyrate and, consequently, to a decrease in its beneficial effects in relation to CRC.
Cyclooxygenase-2 (COX-2) overexpression plays an important role in the inflammation–carcinogenesis pathway of CRC [94] and it is well established that the regular use of NSAIDs exerts a protective effect against CRC development [95]. In this context, we verified that acetylsalicylic acid stimulated butyrate uptake and potentiated its antiproliferative effect, suggesting that the potentiation of the anticarcinogenic effect of BT in Caco-2 cells is related to the increase in its cellular uptake [42].

6. Conclusions and Future Perspectives

In conclusion, the existing evidence points to the conclusion that all the butyrate transporters at the intestinal mucosal level (MCT1, SMCT1, MCT4, and BCRP) can be modulated both by redox and inflammatory status. A role of Nrf2, TNF-α, and IFN-γ in mediating the effect of oxidative stress and inflammation, respectively, on MCT1 and SMCT1 is suggested. Moreover, colonic inflammation/TNF-α and IFN-γ appear to negatively impact MCT1, SMCT1, and BCRP, while positively impacting MCT4. This suggests that these conditions will be associated with decreased intracellular levels of butyrate, which will result in a diminution of the protective effects of this compound at the colonic level.
However, for all transporters, the evidence is very scarce and inconsistent. So, more investigation is needed that specifically can address the effect of distinct ROS species and antioxidant mechanisms and their mode of action in regulating the activity of these transporters. Similarly, additional work examining in greater depth the effect of distinct inflammatory modulators and their specific mode of action resulting in changes in butyrate activity is also needed. Specifically, it would be important to investigate the effects of oxidative stress and inflammatory cytokines at the posttranslational level, because the activity and membrane location of these transporters are regulated both by phosphorylation/dephosphorylation and by intracellular signaling pathways such as nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), mitogen-activated protein kinase (MAPK), and Janus kinase/signal transducer and activator of transcription (JAK/STAT), which are known molecular targets of both oxidative stress and inflammation [96]. Knowledge on regulation of butyrate transport mechanisms at the colonic level by oxidative stress and inflammation is very important, given the important beneficial role of this SCFA at that level and the fact that increased oxidative stress levels and inflammatory status are present in a series of intestinal conditions and pathologies. In this context, it would also be important to compare the effects of acute and chronic oxidative stress and inflammation, which are relevant from a medical point of view. Additionally, further work investigating the link between changes in butyrate transport and its beneficial effects at the colonic level would certainly help to clearly establish these transporters as potential cellular targets in CRC and IBD.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

We used ChatGPT (GPT-5.1, OpenAI) to assist in formatting and organizing the Figures in this manuscript. All content was reviewed and verified by the author.

Conflicts of Interest

The author declares no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ALSAmyotrophic lateral sclerosis
BCRPBreast cancer resistance protein
BTButyrate
CRCColorectal cancer
GPRG-protein-coupled receptors
HDACsHistone deacetylases
IBDInflammatory bowel disease
IFN-γInterferon-gamma
LPSLipopolysaccharide
MCT1Monocarboxylate transporter 1
MCT4Monocarboxylate transporter 4
NSAIDsNon-steroidal anti-inflammatory drugs
NRF2Nuclear factor erythroid 2-related factor 2
ROSReactive oxygen species
SCFAShort-chain fatty acid
SMCT1Sodium-coupled monocarboxylate transporter 1
TNF-αTumor necrosis factor-alpha

References

  1. Couto, M.R.; Gonçalves, P.; Magro, F.; Martel, F. Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacol. Res. 2020, 159, 104947. [Google Scholar] [CrossRef]
  2. Gonçalves, P.; Martel, F. Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer. Porto Biomed. J. 2016, 1, 83–91. [Google Scholar] [CrossRef]
  3. Astbury, S.M.; Corfe, B.M. Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature. Curr. Drug Metab. 2012, 13, 815–821. [Google Scholar] [CrossRef] [PubMed]
  4. Ganapathy, V.; Thangaraju, M.; Prasad, P.D.; Martin, P.M.; Singh, N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr. Opin. Pharmacol. 2013, 13, 869–874. [Google Scholar] [CrossRef]
  5. Gonçalves, P.; Martel, F. Butyrate and Colorectal Cancer: The Role of Butyrate Transport. Curr. Drug Metab. 2013, 14, 994–1008. [Google Scholar] [CrossRef]
  6. Sivaprakasam, S.; Bhutia, Y.D.; Yang, S.P.; Ganapathy, V. Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis. Compr. Physiol. 2018, 8, 299–314. [Google Scholar] [CrossRef]
  7. Gonçalves, P.; Gregório, I.; Martel, F. The short-chain fatty acid butyrate is a substrate of breast cancer resistance protein. Am. J. Physiol.-Cell Physiol. 2011, 301, C984–C994. [Google Scholar] [CrossRef]
  8. Aramouni, K.; Assaf, R.; Shaito, A.; Fardoun, M.; Al-Asmakh, M.; Sahebkar, A.; Eid, A.H. Biochemical and cellular basis of oxidative stress: Implications for disease onset. J. Cell Physiol. 2023, 238, 1951–1963. [Google Scholar] [CrossRef]
  9. Hassan, H.A.; Ahmed, H.S.; Hassan, D.F. Free radicals and oxidative stress: Mechanisms and therapeutic targets. Hum. Antibodies 2024, 32, 151–167. [Google Scholar] [CrossRef]
  10. Klaunig, J.E. Oxidative Stress and Cancer. Curr. Pharm. Design 2018, 24, 4771–4778. [Google Scholar] [CrossRef]
  11. Pisoschi, A.M.; Pop, A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur. J. Med. Chem. 2015, 97, 55–74. [Google Scholar] [CrossRef]
  12. Bhattacharyya, A.; Chattopadhyay, R.; Mitra, S.; Crowe, S.E. Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases. Physiol. Rev. 2014, 94, 329–354. [Google Scholar] [CrossRef]
  13. Sun, Y.Q.; Wang, X.R.; Li, L.; Zhong, C.; Zhang, Y.; Yang, X.D.; Li, M.Y.; Yang, C. The role of gut microbiota in intestinal disease: From an oxidative stress perspective. Front. Microbiol. 2024, 15, 1328324. [Google Scholar] [CrossRef]
  14. Vona, R.; Pallotta, L.; Cappelletti, M.; Severi, C.; Matarrese, P. The Impact of Oxidative Stress in Human Pathology: Focus on Gastrointestinal Disorders. Antioxidants 2021, 10, 201. [Google Scholar] [CrossRef]
  15. Kuo, M.T. Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities. Antioxid. Redox Signal. 2009, 11, 99–133. [Google Scholar] [CrossRef]
  16. Matalon, S.; Hardiman, K.M.; Jain, L.; Eaton, D.C.; Kotlikoff, M.; Eu, J.P.; Sun, J.H.; Meissner, G.; Stamler, J.S. Regulation of ion channel structure and function by reactive oxygen-nitrogen species. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2003, 285, L1184–L1189. [Google Scholar] [CrossRef]
  17. Ikemura, K.; Iwamoto, T.; Okuda, M. Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: Possible role of oxidative stress in the pathogenesis. Expert. Opin. Drug Met. 2009, 5, 907–920. [Google Scholar] [CrossRef]
  18. Gonçalves, P.; Gregório, I.; Catarino, T.A.; Martel, F. The effect of oxidative stress upon the intestinal epithelial uptake of butyrate. Eur. J. Pharmacol. 2013, 699, 88–100. [Google Scholar] [CrossRef] [PubMed]
  19. Gonçalves, P.; Catarino, T.; Gregório, I.; Martel, F. Inhibition of butyrate uptake by the primary bile salt chenodeoxycholic acid in intestinal epithelial cells. J. Cell Biochem. 2012, 113, 2937–2947. [Google Scholar] [CrossRef] [PubMed]
  20. Diehl, K.; Dinges, L.A.; Helm, O.; Ammar, N.; Plundrich, D.; Arlt, A.; Röcken, C.; Sebens, S.; Schäfer, H. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: A condition favoring metabolic symbiosis between colorectal cancer and stromal cells. Oncogene 2018, 37, 39–51. [Google Scholar] [CrossRef]
  21. Wang, L.J.; Zhu, R.X.; Wang, J.H.; Yu, S.W.; Wang, J.X.; Zhang, Y. Nrf2 Activation Enhances Muscular MCT1 Expression and Hypoxic Exercise Capacity. Med. Sci. Sports Exerc. 2020, 52, 1719–1728. [Google Scholar] [CrossRef]
  22. Ammar, N.; Hildebrandt, M.; Geismann, C.; Röder, C.; Gemoll, T.; Sebens, S.; Trauzold, A.; Schäfer, H. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism. Antioxidants 2023, 12, 1818. [Google Scholar] [CrossRef]
  23. Gyawali, A.; Kang, Y.S. Transport Alteration of 4-Phenyl Butyric Acid Mediated by a Sodium- and Proton-Coupled Monocarboxylic Acid Transporter System in ALS Model Cell Lines (NSC-34) Under Inflammatory States. J. Pharm. Sci. 2021, 110, 1374–1384. [Google Scholar] [CrossRef]
  24. De Saedeleer, C.J.; Porporato, P.E.; Copetti, T.; Pérez-Escuredo, J.; Payen, V.L.; Brisson, L.; Feron, O.; Sonveaux, P. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration. Oncogene 2014, 33, 4060–4068. [Google Scholar] [CrossRef]
  25. Pinzón-Daza, M.L.; Cuellar-Saenz, Y.; Nualart, F.; Ondo-Mendez, A.; Del Riesgo, L.; Castillo-Rivera, F.; Garzón, R. Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions. J. Cell Biochem. 2017, 118, 1868–1878. [Google Scholar] [CrossRef]
  26. Ogura, J.; Kuwayama, K.; Sasaki, S.; Kaneko, C.; Koizumi, T.; Yabe, K.; Tsujimoto, T.; Takeno, R.; Takaya, A.; Kobayashi, M.; et al. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen. Biochem. Pharmacol. 2015, 97, 89–98. [Google Scholar] [CrossRef]
  27. Semelakova, M.; Jendzelovsky, R.; Fedorocko, P. Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells. Biomed. Pharmacother. 2016, 81, 38–47. [Google Scholar] [CrossRef]
  28. Adachi, T.; Nakagawa, H.; Chung, I.; Hagiya, Y.; Hoshijima, K.; Noguchi, N.; Kuo, M.T.; Ishikawa, T. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Ther. Oncol. 2007, 6, 335–348. [Google Scholar]
  29. Komori, H.; Yamada, K.; Tamai, I. Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells. BBA-Biomembranes 2018, 1860, 973–980. [Google Scholar] [CrossRef]
  30. Miller, D.S. Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly. Adv. Cancer Res. 2015, 125, 43–70. [Google Scholar]
  31. Verenich, S.; Gerk, P.M. Peroxynitrite and 4-Hydroxynonenal Inactivate Breast Cancer Resistance Protein/ABCG2. Biomed. Res. Int. 2019, 2019, 3891535. [Google Scholar] [CrossRef]
  32. De Preter, V.; Arijs, I.; Windey, K.; Vanhove, W.; Vermeire, S.; Schuit, F.; Rutgeerts, P.; Verbeke, K. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm. Bowel Dis. 2012, 18, 1127–1136. [Google Scholar] [CrossRef] [PubMed]
  33. Erdmann, P.; Bruckmueller, H.; Martin, P.; Busch, D.; Haenisch, S.; Müller, J.; Wiechowska-Kozlowska, A.; Partecke, L.I.; Heidecke, C.D.; Cascorbi, I.; et al. Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis. J. Pharm. Sci. 2019, 108, 1035–1046. [Google Scholar] [CrossRef]
  34. Ferrer-Picón, E.; Dotti, I.; Corraliza, A.M.; Mayorgas, A.; Esteller, M.; Perales, J.C.; Ricart, E.; Masamunt, M.C.; Carrasco, A.; Tristán, E.; et al. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2020, 26, 43–55. [Google Scholar] [CrossRef] [PubMed]
  35. Thibault, R.; De Coppet, P.; Daly, K.; Bourreille, A.; Cuff, M.; Bonnet, C.; Mosnier, J.F.; Galmiche, J.P.; Shirazi-Beechey, S.; Segain, J.P. Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology 2007, 133, 1916–1927. [Google Scholar] [CrossRef] [PubMed]
  36. Li, P.; Luo, J.; Jiang, Y.M.; Pan, X.Y.; Dong, M.L.; Chen, B.X.; Wang, J.H.; Zhou, H.; Jiang, H.D.; Duan, Y.R.; et al. Downregulation of OATP2B1 by proinflammatory cytokines leads to 5-ASA hyposensitivity in Ulcerative colitis. Chem.-Biol. Interact. 2024, 398, 111074. [Google Scholar] [CrossRef] [PubMed]
  37. Borthakur, A.; Anbazhagan, A.N.; Kumar, A.; Raheja, G.; Singh, V.; Ramaswamy, K.; Dudeja, P.K. The probiotic Lactobacillus plantarum counteracts TNF-alpha-induced downregulation of SMCT1 expression and function. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G928–G934. [Google Scholar] [CrossRef]
  38. Godínez-Méndez, L.A.; Vega-Magaña, A.N.; Peña-Rodríguez, M.; Valencia-Hernández, G.A.; Muñoz-Sánchez, G.; Iñiguez-Gutiérrez, L.; López-Roa, R.; Ramos-Márquez, M.E.; Fafutis-Morris, M.; Delgado-Rizo, V. Galactooligosaccharides Promote Gut Barrier Integrity and Exert Anti-Inflammatory Effects in DSS-Induced Colitis Through Microbiota Modulation. Int. J. Mol. Sci. 2025, 26, 7968. [Google Scholar] [CrossRef]
  39. Jayawardena, D.; Tyagi, S.; Nazmi, A.; Olivares-Villagomez, D.; Dudeja, P.K. Ion Transport Basis of Diarrhea in a Mouse Model of Adoptive T Cell Transfer Colitis. Digest Dis. Sci. 2020, 65, 1700–1709. [Google Scholar] [CrossRef]
  40. Simeoli, R.; Mattace Raso, G.; Pirozzi, C.; Lama, A.; Santoro, A.; Russo, R.; Montero-Melendez, T.; Berni Canani, R.; Calignano, A.; Perretti, M.; et al. An orally administered butyrate-releasing derivative reduces neutrophil recruitment and inflammation in dextran sulphate sodium-induced murine colitis. Br. J. Pharmacol. 2017, 174, 1484–1496. [Google Scholar] [CrossRef] [PubMed]
  41. Couto, M.R.; Andrade, N.; Magro, F.; Martel, F. Bile salts and proinflammatory cytokines inhibit MCT1-mediated cellular uptake of butyrate and interfere with its antiproliferative properties. Exp. Cell Res. 2023, 429, 113670. [Google Scholar] [CrossRef] [PubMed]
  42. Couto, M.R.; Gonçalves, P.; Catarino, T.A.; Martel, F. The Effect of Inflammatory Status on Butyrate and Folate Uptake by Tumoral (Caco-2) and Non-Tumoral (IEC-6) Intestinal Epithelial Cells. Cell J. 2017, 19 (Suppl. 1), 96–105. [Google Scholar]
  43. Tudela, C.V.; Boudry, C.; Stumpff, F.; Aschenbach, J.R.; Vahjen, W.; Zentek, J.; Pieper, R. Down-regulation of monocarboxylate transporter 1 (MCT1) gene expression in the colon of piglets is linked to bacterial protein fermentation and pro-inflammatory cytokine-mediated signalling. Br. J. Nutr. 2015, 113, 610–617. [Google Scholar] [CrossRef]
  44. Souders, C.I.I.; Aristizabal-Henao, J.J.; Patuel, S.J.; Bowden, J.A.; Zubcevic, J.; Martyniuk, C.J. Interaction between Butyrate and Tumor Necrosis Factor α in Primary Rat Colonocytes. Biomolecules 2023, 13, 258. [Google Scholar] [CrossRef] [PubMed]
  45. Boesmans, L.; Ramakers, M.; Arijs, I.; Windey, K.; Vanhove, W.; Schuit, F.; Rutgeerts, P.; Verbeke, K.; De Preter, V. Inflammation-Induced Downregulation of Butyrate Uptake and Oxidation Is Not Caused by a Reduced Gene Expression. J. Cell Physiol. 2015, 230, 418–426. [Google Scholar] [CrossRef]
  46. Kent-Dennis, C.; Penner, G.B. Effects of lipopolysaccharide exposure on the inflammatory response, butyrate flux, and metabolic function of the ruminal epithelium using an ex vivo model. J. Dairy Sci. 2021, 104, 2334–2345. [Google Scholar] [CrossRef]
  47. Deuring, J.J.; de Haar, C.; Koelewijn, C.L.; Kuipers, E.J.; Peppelenbosch, M.P.; van der Woude, C.J. Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. Biochem. J. 2012, 441, 87–93. [Google Scholar] [CrossRef]
  48. Englund, G.; Jacobson, A.; Rorsmon, F.; Artursson, P.; Kindmark, A.; Rönnblom, A. Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis. 2007, 13, 291–297. [Google Scholar] [CrossRef]
  49. Gutmann, H.; Hruz, P.; Zimmermann, C.; Straumann, A.; Terracciano, L.; Hammann, F.; Lehmann, F.; Beglinger, C.; Drewe, J. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion 2008, 78, 154–162. [Google Scholar] [CrossRef]
  50. He, L.Y.; Wang, H.L.; Zhang, Y.H.; Geng, L.L.; Yang, M.; Xu, Z.H.; Zou, K.J.; Xu, W.F.; Gong, S.T. Evaluation of Monocarboxylate Transporter 4 in Inflammatory Bowel Disease and Its Potential Use as a Diagnostic Marker. Dis. Markers 2018, 2018, 2649491. [Google Scholar] [CrossRef]
  51. Zhang, S.X.; Xu, W.F.; Wang, H.L.; Cao, M.W.; Li, M.S.; Zhao, J.H.; Hu, Y.; Wang, Y.D.; Li, S.Y.; Xie, Y.W.; et al. Inhibition of CREB-mediated ZO-1 and activation of NF-κB-induced IL-6 by colonic epithelial MCT4 destroys intestinal barrier function. Cell Proliferat. 2019, 52, e12673. [Google Scholar] [CrossRef]
  52. de Jong, P.R.; González-Navajas, J.M.; Jansen, N.J.G. The digestive tract as the origin of systemic inflammation. Crit. Care 2016, 20, 279. [Google Scholar] [CrossRef]
  53. Vuyyuru, S.K.; Kedia, S.; Sahu, P.; Ahuja, V. Immune-mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn’s disease and ulcerative colitis. JGH Open 2022, 6, 100–111. [Google Scholar] [CrossRef]
  54. Caron, B.; Honap, S.; Peyrin-Biroulet, L. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies. J. Crohns Colitis 2024, 18, ii3–ii15. [Google Scholar] [CrossRef]
  55. Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769–2778. [Google Scholar] [CrossRef]
  56. Abdulla, M.; Mohammed, N. A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances. Biologics 2022, 16, 129–140. [Google Scholar] [CrossRef] [PubMed]
  57. Guan, Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J. Immunol. Res. 2019, 2019, 7247238. [Google Scholar] [CrossRef]
  58. Johnstone, M.; Han, A.; Bennett, N.; Standifer, C.; Smith, A.; Donohoe, D. Characterization of the Pro-inflammatory Cytokine IL-1β on Butyrate Oxidation in Colorectal Cancer Cells. Faseb J. 2016, 30, 1614–1621. [Google Scholar] [CrossRef]
  59. Yang, T.; Li, H.B.; Oliveira, A.C.; Goel, R.; Richards, E.M.; Pepine, C.J.; Raizada, M.K. Transcriptomic signature of gut microbiome-contacting cells in colon of spontaneously hypertensive rats. Physiol. Genomics 2020, 52, 121–132. [Google Scholar] [CrossRef] [PubMed]
  60. Yang, T.; Magee, K.L.; Colon-Perez, L.M.; Larkin, R.; Liao, Y.S.; Balazic, E.; Cowart, J.R.; Arocha, R.; Redler, T.; Febo, M.; et al. Impaired butyrate absorption in the proximal colon, low serum butyrate and diminished central effects of butyrate on blood pressure in spontaneously hypertensive rats. Acta Physiol. 2019, 226, e13256. [Google Scholar] [CrossRef] [PubMed]
  61. Li, C.; Xu, M.M.; Wang, K.; Adler, A.J.; Vella, A.T.; Zhou, B. Macrophage polarization and meta-inflammation. Transl. Res. 2018, 191, 29–44. [Google Scholar] [CrossRef]
  62. Hahn, E.L.; Halestrap, A.P.; Gamelli, R.L. Expression of the lactate transporter MCT1 in macrophages. Shock 2000, 13, 253–260. [Google Scholar] [CrossRef]
  63. Choi, J.S.; Jin, M.J.; Han, H.K. Role of monocarboxylic acid transporters in the cellular uptake of NSAIDs. J. Pharm. Pharmacol. 2005, 57, 1185–1189. [Google Scholar] [CrossRef]
  64. D’Antongiovanni, V.; Antonioli, L.; Benvenuti, L.; Pellegrini, C.; Di Salvo, C.; Calvigioni, M.; Panattoni, A.; Ryskalin, L.; Natale, G.; Banni, S.; et al. Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury. Br. J. Pharmacol. 2023, 180, 3215–3233. [Google Scholar] [CrossRef] [PubMed]
  65. Gonçalves, P.; Araújo, J.R.; Martel, F. Characterization of Butyrate Uptake by Nontransformed Intestinal Epithelial Cell Lines. J. Memb. Biol. 2011, 240, 35–46. [Google Scholar] [CrossRef] [PubMed]
  66. Gonçalves, P.; Araújo, J.R.; Pinho, M.J.; Martel, F. Modulation of butyrate transport in Caco-2 cells. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2009, 379, 325–336. [Google Scholar] [CrossRef] [PubMed]
  67. Gottfried, E.; Lang, S.A.; Renner, K.; Bosserhoff, A.; Gronwald, W.; Rehli, M.; Einhell, S.; Gedig, I.; Singer, K.; Seilbeck, A.; et al. New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells. PLoS ONE 2013, 8, e66987. [Google Scholar] [CrossRef]
  68. Neuhoff, S.; Ungell, A.L.; Zamora, I.; Artursson, P. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci. 2005, 25, 211–220. [Google Scholar] [CrossRef]
  69. Wegner, S.A.; Kim, H.; Avalos, J.L. Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport. PLoS ONE 2024, 19, e0312492. [Google Scholar] [CrossRef]
  70. Babu, E.; Ananth, S.; Veeranan-Karmegam, R.; Coothankandaswamy, V.; Smith, S.B.; Boettger, T.; Ganapathy, V.; Martin, P.M. Transport via SLC5A8 (SMCT1) Is Obligatory for 2-Oxothiazolidine-4-Carboxylate to Enhance Glutathione Production in Retinal Pigment Epithelial Cells. Investig. Ophthalmol. Vis. Sci. 2011, 52, 5749–5757. [Google Scholar] [CrossRef]
  71. Cui, D.P.; Morris, M.E. The Drug of Abuse γ-Hydroxybutyrate Is a Substrate for Sodium-Coupled Monocarboxylate Transporter (SMCT) 1 (SLC5A8): Characterization of SMCT-Mediated Uptake and Inhibition. Drug Metab. Dispos. 2009, 37, 1404–1410. [Google Scholar] [CrossRef] [PubMed]
  72. Itagaki, S.; Gopal, E.; Zhuang, L.N.; Fei, Y.J.; Miyauchi, S.; Prasad, P.D.; Ganapathy, V. Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). Pharm. Res.-Dordr 2006, 23, 1209–1216. [Google Scholar] [CrossRef]
  73. Yuri, T.; Kono, Y.; Fujita, T. Transport characteristics of 5-aminosalicylic acid into colonic epithelium: Involvement of sodium-coupled monocarboxylate transporter SMCT1-mediated transport system. Biochem. Bioph Res. Commun. 2020, 524, 561–566. [Google Scholar] [CrossRef]
  74. Ananth, S.; Zhuang, L.; Gopal, E.; Itagaki, S.; Ellappan, B.; Smith, S.B.; Ganapathy, V.; Martin, P. Diclofenac-induced stimulation of SMCT1 (SLC5A8) in a heterologous expression system: A RPE specific phenomenon. Biochem. Biophys. Res. Commun. 2010, 394, 75–80. [Google Scholar] [CrossRef] [PubMed]
  75. Marabotto, E.; Kayali, S.; Buccilli, S.; Levo, F.; Bodini, G.; Giannini, E.G.; Savarino, V.; Savarino, E.V. Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. Cancers 2022, 14, 4254. [Google Scholar] [CrossRef] [PubMed]
  76. World Health Organization. Colorectal Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer (accessed on 21 November 2025).
  77. Fanizza, J.; Bencardino, S.; Allocca, M.; Furfaro, F.; Zilli, A.; Parigi, T.L.; Fiorino, G.; Peyrin-Biroulet, L.; Danese, S.; D’Amico, F. Inflammatory Bowel Disease and Colorectal Cancer. Cancers 2024, 16, 2943. [Google Scholar] [CrossRef]
  78. Faye, A.S.; Holmer, A.K.; Axelrad, J.E. Cancer in Inflammatory Bowel Disease. Gastroenterol. Clin. 2022, 51, 649–666. [Google Scholar] [CrossRef]
  79. Keller, D.S.; Windsor, A.; Cohen, R.; Chand, M. Colorectal cancer in inflammatory bowel disease: Review of the evidence. Tech. Coloproctol. 2019, 23, 3–13. [Google Scholar] [CrossRef]
  80. Cuff, M.; Dyer, J.; Jones, M.; Shirazi-Beechey, S. The human colonic monocarboxylate transporter Isoform 1: Its potential importance to colonic tissue homeostasis. Gastroenterology 2005, 128, 676–686. [Google Scholar] [CrossRef]
  81. Gupta, N.; Martin, P.M.; Prasad, P.D.; Ganapathy, V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006, 78, 2419–2425. [Google Scholar] [CrossRef]
  82. Hadjiagapiou, C.; Schmidt, L.; Dudeja, P.K.; Layden, T.J.; Ramaswamy, K. Mechanism(s) of butyrate transport in Caco-2 cells: Role of monocarboxylate transporter 1. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279, G775–G780. [Google Scholar] [CrossRef]
  83. Koukourakis, M.I.; Giatromanolaki, A.; Harris, A.L.; Sivridis, E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66, 632–637. [Google Scholar] [CrossRef]
  84. Pinheiro, C.; Longatto, A.; Scapulatempo, C.; Ferreira, L.; Martins, S.; Pellerin, L.; Rodrigues, M.; Alves, V.A.F.; Schmitt, F.; Baltazar, F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008, 452, 139–146. [Google Scholar] [CrossRef]
  85. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G.F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24, 506–513. [Google Scholar] [CrossRef]
  86. Liu, H.G.; Pan, Y.F.; You, J.; Wang, O.C.; Huang, K.T.; Zhang, X.H. Expression of ABCG2 and its Significance in Colorectal Cancer. Asian Pac. J. Cancer Prev. 2010, 11, 845–848. [Google Scholar] [PubMed]
  87. Nakanishi, T.; Ross, D.D. Breast cancer resistance protein (BCRP/ABCG2): Its role in multidrug resistance and regulation of its gene expression. Chin. J. Cancer 2012, 31, 73–99. [Google Scholar] [CrossRef]
  88. Thangaraju, M.; Cresci, G.; Itagaki, S.; Mellinger, J.; Browning, D.D.; Berger, F.G.; Prasad, P.D.; Ganapathy, V. Sodium-coupled transport of the short chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J. Gastrointest. Surg. 2008, 12, 1773–1781. [Google Scholar] [CrossRef]
  89. Rana, A.; Samtiya, M.; Dhewa, T.; Mishra, V.; Aluko, R.E. Health benefits of polyphenols: A concise review. J. Food Biochem. 2022, 46, e14264. [Google Scholar] [CrossRef] [PubMed]
  90. Sanchez-Tena, S.; Vizan, P.; Dudeja, P.K.; Centelles, J.J.; Cascante, M. Green tea phenolics inhibit butyrate-induced differentiation of colon cancer cells by interacting with monocarboxylate transporter 1. Biochim. Biophys. Acta 2013, 1832, 2264–2270. [Google Scholar] [CrossRef]
  91. Gonçalves, P.; Araújo, J.R.; Pinho, M.J.; Martel, F. In Vitro Studies on the Inhibition of Colon Cancer by Butyrate and Polyphenolic Compounds. Nutr. Cancer 2011, 63, 282–294. [Google Scholar] [CrossRef] [PubMed]
  92. Kopustinskiene, D.M.; Jakstas, V.; Savickas, A.; Bernatoniene, J. Flavonoids as Anticancer Agents. Nutrients 2020, 12, 457. [Google Scholar] [CrossRef] [PubMed]
  93. Long, J.; Guan, P.; Hu, X.; Yang, L.Y.; He, L.Q.; Lin, Q.L.; Luo, F.J.; Li, J.Z.; He, X.G.; Du, Z.L.; et al. Natural Polyphenols as Targeted Modulators in Colon Cancer: Molecular Mechanisms and Applications. Front. Immunol. 2021, 12, 457. [Google Scholar] [CrossRef]
  94. Yang, L.L.; Akanyibah, F.A.; Yao, D.M.; Jin, T.; Mao, F. The role of COX-2 and its use as a therapeutic target in IBD and related colorectal cancer. Arch. Biochem. Biophys. 2025, 771, e13256. [Google Scholar] [CrossRef]
  95. Katona, B.W.; Weiss, J.M. Chemoprevention of Colorectal Cancer. Gastroenterology 2020, 158, 368–388. [Google Scholar] [CrossRef]
  96. Manful, C.F.; Fordjour, E.; Ikumoinein, E.; Abbey, L.; Thomas, R. Therapeutic Strategies Targeting Oxidative Stress and Inflammation: A Narrative Review. BioChem 2025, 5, 35. [Google Scholar] [CrossRef]
Antioxidants 15 00048 g001
Figure 1. Major causes of intestinal oxidative stress.
Figure 1. Major causes of intestinal oxidative stress.
Antioxidants 15 00048 g001
Antioxidants 15 00048 g002
Figure 2. Major causes of intestinal inflammation.
Figure 2. Major causes of intestinal inflammation.
Antioxidants 15 00048 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Martel, F. Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status. Antioxidants 2026, 15, 48. https://doi.org/10.3390/antiox15010048

AMA Style

Martel F. Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status. Antioxidants. 2026; 15(1):48. https://doi.org/10.3390/antiox15010048

Chicago/Turabian Style

Martel, Fátima. 2026. "Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status" Antioxidants 15, no. 1: 48. https://doi.org/10.3390/antiox15010048

APA Style

Martel, F. (2026). Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status. Antioxidants, 15(1), 48. https://doi.org/10.3390/antiox15010048

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop